YIDU TECH (02158) secures an 8.6 million yuan order from the Changzhou campus of Shouer Hospital, with the growth in orders from top three hospitals continuing after reaching a profitability turning point.

On August 10, Hong Kong-listed AI medical leader YIDU TECH (02158) announced its bidding success. Its subsidiary, Yidu Cloud (Beijing) Technology Co., Ltd., successfully won the bid for the information technology support construction project at the Capital Institute of Pediatrics Affiliated Capital Children's Medical Center, Tongzhou District, with a total project amount of approximately 8.6 million yuan. This bid marks another benchmark project in the Beijing region after the company achieved profitability in fiscal year 2026, confirming the implementation capability of its AI Hospital solutions in top-tier public hospitals. It is understood that the project at the Capital Institute of Pediatrics Affiliated Capital Children's Medical Center, Tongzhou District, is a key initiative to implement the overall urban planning requirements of Beijing and alleviate non-capital functions. It is beneficial for promoting the rational layout of high-quality pediatric medical resources, supplementing the shortage of pediatric medical resources in the city's sub-center, and enhancing the overall level of pediatric diagnosis and treatment in surrounding areas. This year, the Beijing municipal government work report has clearly stated the priority task of promoting the "basic completion of the Tongzhou District of the Capital Institute of Pediatrics." Industry insiders believe that this bid not only signifies YIDU TECH's further entry into important projects for the expansion of high-quality medical resources in Beijing but also provides a new application window for its medical data governance and AI capabilities in high-level pediatric medical scenarios. Pediatric diagnosis and treatment present challenges such as a complex spectrum of diseases, a wide age range, and high difficulty in data standardization, thus imposing higher requirements for the data governance of medical information infrastructure, system collaboration, and intelligent support capabilities. Participating in the information technology support construction of the Tongzhou District is expected to further validate YIDU TECH's project implementation and technical service capabilities in complex clinical scenarios, while also enhancing the coverage of the company's public tertiary hospital landscape. As of now, YIDU TECH's AI medical solutions have been implemented in 133 leading tertiary hospitals nationwide, covering various benchmark medical institutions, including Peking Union Medical College Hospital, Peking University Cancer Hospital, and Tsinghua Changgung Hospital. This bid coincides with a historic turning point for the company's fundamentals, with multiple favorable factors supporting the logic of order expansion. On June 30, YIDU TECH released its full-year performance for fiscal year 2026 (ending March 31, 2026), reporting total revenue of 820 million yuan, a year-on-year increase of 14.6%; annual net profit reached 78.766 million yuan, significantly reversing a loss of 135 million yuan in the previous fiscal year, with performance exceeding the top end of prior profit forecasts. The quality of earnings has also significantly improved, with an overall gross margin rising to 36.4%, and adjusted EBITDA soaring 462% year-on-year to 220 million yuan. In the second half of the year, operating cash flow successfully turned positive, with net operating cash flow outflow reduced by 91.2% year-on-year, and the company's ability to generate cash commercially has fully taken shape. In addition to the performance achievement, the company has simultaneously released multiple signals of shareholder return. The board proposed to distribute the first-ever final dividend since its listing, at 0.04 HKD per share, conveying the management's strong confidence in long-term cash flow; in the first half of 2026, the company continued significant share buybacks, with a total of approximately 42.69 million shares repurchased throughout the year, demonstrating the internal team's recognition of the long-term value of AI healthcare.